Stoke Therapeutics, a Bedford, Mass.-based biotechnology company, completed a $90m Series B financing.
The round was led by RTW Investments with participation from founding investor Apple Tree Partners and new investors RA Capital Management, Cormorant Asset Management, Perceptive Advisors, funds managed by Janus Henderson Investors, Redmile Group, Sphera Funds Management, and Alexandria Venture Investments. In conjunction with the funding, Roderick Wong, M.D. from RTW Investments, Matthew Hammond, Ph.D. from RA Capital, and Bihua Chen from Cormorant Asset Management, joined the Board of Directors as observers.
The company intends to use the funds to advance its pipeline of antisense oligonucleotide medicines for Dravet Syndrome and other severe genetic diseases.
Led by Edward M. Kaye, M.D., chief executive officer, Stoke Therapeutics is a biotechnology company working to increase gene expression to treat a wide array of severe genetic diseases, including genetic conditions affecting the central nervous system, eye, ear, liver, and kidney.
Stoke has identified thousands of genes that could be addressed by its proprietary TANGO technology, which targets non-productive RNA splicing to increase gene expression and address the root cause of monogenic diseases caused by loss or reduction of gene function.